Evidence map›Paper›PMID 40124894›Full record

ArticleFrontiers in microbiology2025

Isolation, characterization, and genomic analysis of a novel bacteriophage vB_Kp_XP4 targeting hypervirulent and multidrug-resistant

Xiaocui Peng, Jianliang Chang, Hongxia Zhang, Xiaoyu Li, Changhong Zhang, Shiyan Jiao, Chengxiu Lv, Na Wang, Jun Zhao, Bu Wang and 2 more

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Frontiers in cellular and infection microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiaocui Peng *Department of Postgraduate, Hebei North University, Zhangjiakou, China.
Jianliang Chang *Department of Postgraduate, Hebei North University, Zhangjiakou, China.
Hongxia ZhangRespiratory and Critical Care Medicine Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Xiaoyu LiDepartment of Postgraduate, Hebei North University, Zhangjiakou, China.
Changhong ZhangRespiratory and Critical Care Medicine Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Shiyan JiaoDepartment of Postgraduate, Hebei North University, Zhangjiakou, China.
Chengxiu LvDepartment of Clinical Laboratory, Zibo First Hospital, Zibo, China.
Na WangCentral Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Jun ZhaoDepartment of Postgraduate, Hebei North University, Zhangjiakou, China.
Bu WangRespiratory and Critical Care Medicine Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Wei ZhangCentral Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Zhihua ZhangRespiratory and Critical Care Medicine Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hypervirulent and multidrug-resistant Methods: The phage vB_Kp_XP4 was isolated from river water using the double-layer agar plate method with the clinically isolated strain P4 as the host. Morphology was analyzed via transmission electron microscopy (TEM). Host range, pH, and thermal stability were assessed using spot assays and OD Results: TEM revealed Phage vB_Kp_XP4 as a tailed phage with an icosahedral head and a long, flexible tail. It lysed an hvKP strain (carrying Conclusion: Phage vB_Kp_XP4 exhibits high stability, specificity, potent lytic activity, and no undesirable genes, demonstrating effective in vivo therapeutic efficacy, suggest its potential for clinical applications against

Indexed as

biological characteristicshypervirulenceKlebsiella pneumoniaemultidrug resistancephage therapywhole-genome sequencing

Identifiers

PMID40124894
PMCPMC11925924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.